{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:03:30Z","timestamp":1789736610206,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41375-021-01299-x","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:02:53Z","timestamp":1621836173000},"page":"2710-2714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-5123","authenticated-orcid":false,"given":"Giuseppe","family":"Gritti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Alborghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frigeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Luca","family":"Lorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-248X","authenticated-orcid":false,"given":"Luca","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M. J.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan J. K.","family":"Kanhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana Tonkovic","family":"Reljanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-0504","authenticated-orcid":false,"given":"Fabiano","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical\u2013therapeutic staging proposal. J Heart Lung Transpl. 2020;39:405\u20137.","journal-title":"J Heart Lung Transpl"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet."},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17\u201341.","journal-title":"J Leukoc Biol"},{"key":"1299_CR4","unstructured":"SYLVANT 100 mg powder for concentrate for solution for infusion \u2013 Summary of Product Characteristics (SmPC) \u2013 (emc). https:\/\/www.medicines.org.uk\/emc\/product\/2132\/smpc."},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2020.5394","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574\u201381.","journal-title":"JAMA"},{"key":"1299_CR6","doi-asserted-by":"publisher","unstructured":"Gritti G, Raimondi F, Ripamonti D, Riva I, Landi F, Alborghetti L, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.01.20048561.","DOI":"10.1101\/2020.04.01.20048561"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-020-00832-x","volume":"22","author":"E Brunetta","year":"2021","unstructured":"Brunetta E, Folci M, Bottazzi B, De Santis M, Gritti G, Protti A, et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2021;22:19\u201324.","journal-title":"Nat Immunol"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jinf.2020.10.027","volume":"82","author":"A Schirinzi","year":"2021","unstructured":"Schirinzi A, Pesce F, Laterza R, D\u2019Alise MG, Lovero R, Fontana A, et al. Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients admitted to the emergency department. J Infect. 2021;82:84\u2013123.","journal-title":"J Infect"},{"key":"1299_CR9","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. Nat Med. 2020;26:1636\u201343.","journal-title":"Nat Med."},{"key":"1299_CR10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1182\/bloodadvances.2020003568","volume":"5","author":"ML Meizlish","year":"2021","unstructured":"Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Adv. 2021;5:1164\u201377.","journal-title":"Blood Adv"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Foss\u00e5 A, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966\u201374.","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1038\/s41375-021-01329-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01299-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T05:10:56Z","timestamp":1630473056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01299-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.01.20048561","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-021-01329-8","URL":"https:\/\/doi.org\/10.1038\/s41375-021-01329-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JPM, BMJO, and KJKK are employees of EUSA Pharma. AR reports consultancy fees from Amgen, Celgene, Gilead, Italfarmaco, Novartis, Omeros, Pfizer, and Roche; travel support from Amgen, Celgene, Gilead, Italfarmaco, Novartis, and Roche; and research grants from Amgen, Italfarmaco, and Roche. CM reports travel support from Medac. DR reports personal fees from Gilead, Janssen, and ViiV. FDM reports grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis; and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Guidotti\/Malesci, Menarini, Mundipharma, Novartis, Teva, and Zambon. GG reports non-financial support from Gilead Kite, Janssen, Roche, and Takeda; and personal fees from Amgen, Autolus, Gilead Kite, Italfarmaco, IQVIA, Roche, and Takeda. IR reports travel support from Aferetica. SF reports grants from Gilead and Novartis; and personal fees from AbbVie, Astellas, Bayer, Gilead, Intercept, Kedrion, Merck Sharp & Dohme, and Novartis. BB and AM are inventors of patents on PTX3 and obtain royalties on related reagents. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We complied with all relevant ethical rules. The protocol and informed consent forms were approved by the Hospital Ethics Board at the Papa Giovanni XXIII Hospital in Bergamo, Italy. Patients, or their legal representative, provided either verbal or written consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}